- Home
- ZBAI vs PRPO Comparison
ZBAI vs PRPO Comparison
Compare ZBAI & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- PRPO
- Stock Information
- Founded
- ZBAI 2015
- PRPO N/A
- Country
- ZBAI United States
- PRPO United States
- Employees
- ZBAI N/A
- PRPO N/A
- Industry
- ZBAI Professional Services
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- ZBAI Consumer Discretionary
- PRPO Industrials
- Exchange
- ZBAI Nasdaq
- PRPO Nasdaq
- Market Cap
- ZBAI 9.9M
- PRPO 8.8M
- IPO Year
- ZBAI N/A
- PRPO N/A
- Fundamental
- Price
- ZBAI N/A
- PRPO $5.27
- Analyst Decision
- ZBAI
- PRPO
- Analyst Count
- ZBAI 0
- PRPO 0
- Target Price
- ZBAI N/A
- PRPO N/A
- AVG Volume (30 Days)
- ZBAI 146.5K
- PRPO 5.8K
- Earning Date
- ZBAI 12-19-2024
- PRPO 11-06-2024
- Dividend Yield
- ZBAI N/A
- PRPO N/A
- EPS Growth
- ZBAI N/A
- PRPO N/A
- EPS
- ZBAI N/A
- PRPO N/A
- Revenue
- ZBAI $495,000.00
- PRPO $17,411,000.00
- Revenue This Year
- ZBAI N/A
- PRPO $75.18
- Revenue Next Year
- ZBAI N/A
- PRPO N/A
- P/E Ratio
- ZBAI N/A
- PRPO N/A
- Revenue Growth
- ZBAI N/A
- PRPO 31.31
- 52 Week Low
- ZBAI $0.58
- PRPO $4.31
- 52 Week High
- ZBAI $1.50
- PRPO $7.30
- Technical
- Relative Strength Index (RSI)
- ZBAI N/A
- PRPO 32.33
- Support Level
- ZBAI N/A
- PRPO $5.72
- Resistance Level
- ZBAI N/A
- PRPO $6.48
- Average True Range (ATR)
- ZBAI 0.00
- PRPO 0.24
- MACD
- ZBAI 0.00
- PRPO -0.05
- Stochastic Oscillator
- ZBAI 0.00
- PRPO 3.98
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.